Lees K R
University Department of Medicine and Therapeutics, Western Infirmary, Glasgow, UK.
J Hypertens Suppl. 1992 Jul;10(5):S3-11.
CURRENT USAGE: Plasma angiotensin converting enzyme (ACE) inhibition and dose-response relationships during blood pressure reductions were compared for several marketed ACE inhibitor compounds. Both peak and trough responses are considered and contrasted. The presently recommended antihypertensive doses of enalapril, lisinopril, perindopril and ramipril appear to lie within the linear range of the antihypertensive dose-response relationship. For benazepril and captopril, the recommended doses may be in the flat, upper part of the relationship.
The recommended doses for initiating antihypertensive therapy may still be excessive in patients at risk of heightened pharmacodynamic responses. Further studies are required to clarify the dose-response relationship for all of these compounds.
当前应用情况:比较了几种市售血管紧张素转换酶(ACE)抑制剂化合物在降低血压过程中的血浆ACE抑制作用及剂量反应关系。同时考虑并对比了峰值和谷值反应。依那普利、赖诺普利、培哚普利和雷米普利目前推荐的抗高血压剂量似乎处于抗高血压剂量反应关系的线性范围内。对于贝那普利和卡托普利,推荐剂量可能处于该关系的平坦、较高部分。
对于有药效学反应增强风险的患者,起始抗高血压治疗的推荐剂量可能仍然过高。需要进一步研究以阐明所有这些化合物的剂量反应关系。